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ABSTRACT
Introduction: The inhaled corticosteroid, 
fluticasone propionate (fluticasone), and the 
long-acting beta2-agonist, formoterol fumarate 
(formoterol), have been combined in a single 
aerosol inhaler (fluticasone/formoterol).
In a randomized, open-label study, fluticasone/
formoterol showed similar efficacy to fluticasone/
salmeterol after 12 weeks of treatment. This 
post-hoc analysis compared the onset of 
bronchodilation with the two treatments.
Methods: Adults with mild-to-moderate-
severe persistent asthma were randomized to 
fluticasone/formoterol (100/10 or 250/10 μg 
twice daily [b.i.d.]) or fluticasone/salmeterol 
(100/50 or 250/50 μg b.i.d.) for 12 weeks. The 
onset of bronchodilation (the first post-dose time 
point at which the forced expiratory volume 
in 1 second [FEV1] was ≥12% greater than the 
pre-dose value), responder rates (the proportion of 
patients achieving bronchodilation), and changes 
in FEV1 were assessed at days 0 (baseline) and 84.
Results: Fluticasone/formoterol (n = 101) 
provided more rapid onset of bronchodilation 
than fluticasone/salmeterol (n = 101) over the 
first 120 min post-dose on days 0 (hazard ratio 
[HR] = 1.47 [95% CI 1.05–2.05]) and 84 (HR = 1.77 
[95% CI 1.14–2.73]). The odds of a patient 
achieving bronchodilation within 5 min of 
dosing were almost four-times higher with 
fluticasone/formoterol than with fluticasone/
salmeterol on day 0 (odds ratio [OR] = 3.97 
[95% CI 1.96–8.03]) and almost 10-times higher 
on day 84 (OR = 9.58 [95% CI 2.14–42.90]); 
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barriers to control, such as comorbidities, 
smoking, under-treatment, and suboptimal 
inhaler technique. Achieving asthma control is 
also hindered by perceptual barriers, contributing 
to reduced patient adherence to treatment 
regimens [8, 9]. Studies have suggested that 
therapies with a rapid onset of bronchodilation 
may encourage adherence and, thus, improve 
real-world asthma outcomes [10, 11].
An additional ICS/LABA combination has 
been developed for the treatment of asthma. It 
combines the potent ICS, fluticasone propionate 
(fluticasone) [3, 12], with the rapid-acting LABA, 
formoterol fumarate (formoterol) [13, 14], in 
a single hydrofluoroalkane aerosol inhaler 
(fluticasone/formoterol; flutiform®; registered 
trademark of Jagotec AG, Muttenz, Switzerland, 
which is used under licence). The inclusion 
of formoterol in this combination would be 
expected to produce a rapid-onset bronchodilatory 
effect [13, 14]. Formoterol has been shown 
to reverse methacholine-induced severe 
bronchoconstriction more rapidly than salmeterol 
xinafoate (salmeterol) and as rapidly as the short-
acting beta2-agonist, salbutamol [13, 15].
The authors have previously reported the 
results of a randomized, open-label study, which 
showed that fluticasone/formoterol provides 
comparable improvements in lung function 
and measures of asthma control to fluticasone/
salmeterol over 12 weeks of treatment in patients 
with mild-to-moderate-severe asthma [16]. 
Notably, fluticasone/formoterol had a 
significantly faster onset of bronchodilation 
(defined as the first post-dose time point at 
which the forced expiratory volume in 1 second 
[FEV1] was at least 12% greater than the pre-dose 
value) than fluticasone/salmeterol throughout 
the course of the study (overall hazard ratio 
[HR] = 1.64 [95% CI 1.28–2.10]; P < 0.001).
Here, the authors report the results of a 
post-hoc analysis of data from this study, 
the odds of achieving bronchodilation within 
120 min post-dose were approximately twofold 
higher with fluticasone/formoterol on both days. 
The overall percentage increase in least-squares 
(LS) mean FEV1 during the 120-min post-dose 
period was significantly greater with fluticasone/
formoterol than fluticasone/salmeterol on days 0 
(LS mean treatment difference: 4.70% [95% CI 
1.57–7.83]; P = 0.003) and 84 (2.79% [95% CI 
0.65–4.93]; P = 0.011).
Conclusion: These analyses showed that 
fluticasone/formoterol provided a faster onset 
of bronchodilation than fluticasone/salmeterol, 
which was maintained over 12 weeks of 
treatment. This benefit may facilitate treatment 
adherence among patients with asthma.
Keywords:  Asthma; Bronchodilat ion; 
Combination therapy; Fluticasone; Forced 
expiratory volume; Formoterol; Inhaled 
corticosteroid; Long-acting beta2-agonist; 
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INTRODUCTION
Asthma is one of the most common chronic 
diseases in the world, and is associated with 
substantial direct and indirect healthcare costs, as 
well as significant morbidity and mortality [1, 2]. 
The combination of an inhaled corticosteroid 
(ICS) and a long-acting beta2-agonist (LABA) is a 
highly efficacious treatment option for asthma, 
and is advocated by treatment guidelines for use 
in patients whose asthma is not controlled with 
an ICS alone [3]. Indeed, data from randomized 
clinical trials suggest that asthma control can be 
achieved with ICS/LABA therapy in the majority 
of patients [4, 5].
Despite the availability of several ICS/LABA 
combination therapies, many patients in the real 
world have suboptimal asthma control [6, 7]. This 
may reflect the presence of practical and physical 
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Patients
Men and women (≥18 years old) with a 
history of mild-to-moderate-severe persistent 
asthma for at least 6 months before screening 
were eligible for inclusion in this study. 
Patients were also required to have an FEV1 of 
≥40–≤85% of predicted normal values following 
appropriate withholding of asthma medications. 
In addition, patients had to show reversibility in 
FEV1 of ≥15% after salbutamol inhalation (two 
actuations, 100 μg per actuation) from the pre-
salbutamol value. If reversibility was not met, 
salbutamol administration was repeated and 
reversibility re-assessed. If the subject still failed 
to show reversibility, the test could be repeated 
at a separate, unscheduled visit before the 
randomization visit. Only patients who could 
demonstrate correct inhaler technique were 
eligible for inclusion. Exclusion criteria included 
life-threatening asthma within the past year, and 
hospitalization or emergency department visit 
for asthma in the 4 weeks prior to screening.
Study Treatments
Patients were randomly assigned (1:1) to 
receive 12 weeks of treatment with fluticasone/
formoterol (two actuations of 50/5 μg or 125/5 μg 
every 12 h [i.e., 100/10 μg or 250/10 μg 
twice daily]), or fluticasone/salmeterol (two 
actuations of 50/25 μg or 125/25 μg every 12 h 
[i.e., 100/50 μg or 250/50 μg twice daily]). The 
starting dose for either treatment was selected 
based on each patient’s asthma history and pre-
study medication. Patients who required an 
ICS at doses of 100–250 μg/day (fluticasone or 
equivalent doses of another ICS) received the 
lower dose of study medication; those who 
required an ICS at doses of 250–1,000 μg/day 
(fluticasone or equivalent doses of another ICS) 
received the higher dose of study medication. 
conducted to characterize further the speed 
of onset of bronchodilation with fluticasone/
formoterol compared with fluticasone/salmeterol.
MATERIALS AND METHODS
Full details on the methodology of this study 
(including further information on inclusion and 
exclusion criteria, the randomization procedure 
and dose allocation, study assessments, and 
statistical analyses) have been published 
previously [16]. The details relevant to this 
post-hoc analysis are presented briefly here.
Study Design
This was a 12-week, open-label, randomized, 
active-controlled, parallel-group, phase 3 
study, conducted in 25 European centers in 
five countries (Germany, Hungary, Poland, 
Romania, and the UK; ClinicalTrials.gov 
identifier: NCT00476073). The study was 
performed in accordance with the Declaration 
of Helsinki and Good Clinical Practice 
guidelines, and approved by independent 
ethics committees in each of the participating 
countries. Written informed consent was 
obtained from all participating patients.
This study consisted of a screening phase 
of 4–10 days to assess eligibility, after which 
eligible patients were randomized to treatment 
and entered the 12-week active treatment 
phase. The study was designed to demonstrate 
non-inferiority of fluticasone/formoterol 
compared with fluticasone/salmeterol in 
controlling mild-to-moderate-severe persistent 
asthma in adult patients; the primary efficacy 
measure was mean pre-dose FEV1. Onset of 
bronchodilation (defined as the first post-dose 
time point at which FEV1 was at least 12% 
greater than the pre-dose value) was assessed 
as a secondary endpoint.
Adv Ther (2012)  29(11):958–69. 961
Patients receiving the lower dose were 
permitted to switch to the higher dose if their 
asthma was uncontrolled. Both treatments 
were administered via a hydrofluoroalkane 
pressurized metered-dose inhaler with an 
AeroChamber Plus® spacer device (AeroChamber 
Plus®; registered trademark of Trudell Medical 
International, Ontario, Canada). The use 
of salbutamol (two actuations, 100 μg per 
actuation, up to four times per day) was 
permitted as rescue medication.
Assessments
Lung function tests were performed in the 
30 min prior to the administration of study 
medication and repeated 5, 10, 30, 60, 90, and 
120 min post-dose, on day 0 (baseline) and on 
days 14, 42, and 84. 
Onset of bronchodilation was assessed as part 
of the original study. Additional analyses were 
performed post-hoc on data from day 0 and day 
84 to characterize further the bronchodilation 
profile of fluticasone/formoterol compared with 
that of fluticasone/salmeterol. These included 
assessments of responder rates (defined as 
the proportion of patients achieving onset of 
bronchodilation) within 5 min and within 
120 min post-dose for each treatment group, 
and the percentage changes in FEV1 and actual 
changes in least-squares (LS) mean FEV1 from 
pre-dose to 5, 10, 30, 60, 90, and 120 min 
post-dose. The use of LS means allows for 
adjustments for differences between the groups 
in other factors that may affect the change in 
FEV1 (see Statistical Analyses section for details).
Statistical Analyses
In the original, pre-planned study analysis, 
the onset of bronchodilation was assessed 
for the intention-to-treat (ITT) population 
using a multiple failures time model, and 
Kaplan-Meier plots were produced, by visit, 
for each treatment. Patients with no pre-dose 
measurement were excluded from the analysis 
for that visit, and those who did not achieve 
onset of bronchodilation within 120 min post-
dose were censored at that point. 
In the post-hoc analysis, HRs for the onset 
of bronchodilation were calculated post-hoc for 
day 0 and day 84. In addition, odds ratios (ORs) 
for responder rate in the fluticasone/formoterol 
group compared with the fluticasone/salmeterol 
group were determined using logistic regression 
with treatment and dose group as factors. For 
the analysis of percentage and actual changes 
in FEV1 from pre-dose to each post-dose time 
point, LS means were calculated from a repeated-
measures analysis of covariance model with 
treatment, dose, pre-dose FEV1, time point and 
treatment × time point interaction as factors, 
and center as a random effect. Differences in LS 
mean values were determined between the two 
treatment groups overall and for each post-dose 
time point, and P-values were calculated.
The ITT population comprised all randomized 
patients who received study treatment and had 




The ITT population comprised 202 patients. The 
demographics and asthma characteristics of the 
two treatment groups were similar at screening 
(Table 1), including pre-study ICS dose (based on 
the Global Initiative for Asthma 2011 guideline 
on equipotency of ICS [3]) and pre-study LABA 
use. At baseline (day 0), mean pre-dose FEV1
was 2.22 L in the fluticasone/formoterol group 
and 2.20 L in the fluticasone/salmeterol group. 
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During the study, eight patients required a 
change in dose strength from low to high (five 
in the fluticasone/formoterol group and three in 
the fluticasone/salmeterol group).
Onset of Bronchodilation
Fluticasone/formoterol treatment provided 
a faster onset of bronchodilation than 
fluticasone/salmeterol therapy on day 0, and 
this effect was maintained at the end of the 
study. On day 0, fluticasone/formoterol was 
superior to fluticasone/salmeterol for onset of 
bronchodilation over the first 120 min post-dose 
(HR = 1.47; 95% CI 1.05–2.05). Figure 1a 
shows the Kaplan-Meier plot for the onset 
of bronchodilation on day 0 (as published 
previously [16]). Similarly, a significantly more 
rapid onset of bronchodilation with fluticasone/
formoterol was observed on day 84 (HR = 1.77; 
95% CI 1.14–2.73; Fig. 1b). 
Responder rates were greater with fluticasone/
formoterol than with fluticasone/salmeterol 
within 5 min and within 120 min post-dose 
on day 0 and day 84 (Table 2). On day 0, the 
odds of a patient “responding to treatment” 
(i.e., achieving onset of bronchodilation) were 
almost four-times higher with fluticasone/
formoterol than fluticasone/salmeterol within 5 
min post-dose (OR = 3.97; 95% CI 1.96–8.03), 
Table 1  Demographic characteristics, asthma status, and treatment at screening (intention-to-treat population)
Fluticasone/formoterol Fluticasone/salmeterol
(N = 101) (N = 101)
Age, years 47.6 ± 12.6 46.0 ± 12.9
Gender
Male, n (%) 47 (46.5) 39 (38.6)
Female, n (%) 54 (53.5) 62 (61.4)
Race
Caucasian, n (%) 101 (100) 101 (100)
BMI, kg/m2 27.3 ± 4.8 27.1 ± 5.3
FEV1 pre-salbutamol, L 2.1 ± 0.56 2.1 ± 0.52
FEV1 post-salbutamol, L 2.7 ± 0.79 2.6 ± 0.66
Predicted FEV1, L 3.2 ± 0.73 3.1 ± 0.65
FEV1 % predicted 66.1 ± 10.1 68.6 ± 9.2
FEV1 reversibility, % 27.6 ± 12.8 24.9 ± 9.9
Treatment
ICS dose (µg), median (range)a 500 (100–1,000) 400 (100–1,000)
LABA use, n (%) 78 (77.2) 78 (77.2)
Data are shown as mean ± SD unless otherwise stated
BMI body mass index, FEV1 forced expiratory volume in 1 second, ICS inhaled corticosteroid, LABA long-acting beta2-
agonist
a Based on fluticasone equivalent, according to the Global Initiative for Asthma guideline on equipotency of ICS [3]
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and twofold higher within 120 min post-dose 
(OR = 2.03; 95% CI 1.07–3.89). Moreover, on 
day 84, the odds of a patient responding within 
5 min post-dose were almost 10-fold higher with 
fluticasone/formoterol than with fluticasone/
salmeterol (OR = 9.58; 95% CI 2.14–42.90) and 
nearly twofold higher within 120 min post-dose 
(OR = 1.93; 95% CI 1.08–3.43; Table 2).
Changes in FEV1
Fluticasone/formoterol provided more rapid 
bronchodilation than fluticasone/salmeterol 
for change in FEV1 during the 120-min 
post-dose period on day 0 (Fig. 2a) and 
day 84 (Fig. 2b). On day 0, the overall percentage 
increase in LS mean FEV1 was significantly 
greater with fluticasone/formoterol than with 
fluticasone/salmeterol (17.33% vs. 12.63%; 
LS mean treatment difference: 4.70% [95% 
CI 1.57–7.83]; P = 0.003). Similarly, on day 84, 
fluticasone/formoterol provided a significantly 
greater percentage increase in overall LS mean 
FEV1 than fluticasone/salmeterol (8.99% vs. 
6.20%; LS mean treatment difference: 2.79% 
[95% CI 0.65–4.93]; P = 0.011).
The between-group difference in overall 
LS mean change in FEV1 from pre-dose on 
day 0 was statistically significantly in favor 
of fluticasone/formoterol (LS mean treatment 
difference: 0.112 L [95% CI 0.042–0.181]; 
P = 0.002; Table 3). Similarly, on day 84, the 
between-group difference from pre-dose FEV1 in 


































Fluticasone/salmeterol 100/50 µg or 250/50 µg b.i.d. (n = 100)
Fluticasone/formoterol 100/10 µg or 250/10 µg b.i.d. (n = 101)


































Fluticasone/salmeterol 100/50 µg or 250/50 µg b.i.d. (n = 100)
Fluticasone/formoterol 100/10 µg or 250/10 µg b.i.d. (n = 98)
HR = 1.77 (95% CI 1.14–2.73); P = 0.011
(a) (b)
Fig. 1  Kaplan-Meier plots showing the onset of bronchodilation on (a) day 0 and (b) day 84 (intention-to-treat population). 
HRs are from post-hoc analyses. Onset of bronchodilation was defined as the first post-dose time point at which FEV1 was 
at least 12% greater than the pre-dose value. This figure is modified from [16] Bodzenta-Lukaszyk A, Dymek A, McAulay K, 
Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but 
has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med. 2011;11:28. b.i.d. twice daily, HR hazard 
ratio, FEV1 forced expiratory volume in 1 second, CI  confidence interval
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Table 2  Proportion of patients achieving onset of bronchodilation within 5 min and within 120 min post-dose on day 0 and 










Day 0, within 5 min post-dose
n 101 100 – –
Onset of bronchodilationa, n (%) 39 (38.6) 14 (14.0) 24.6 (12.9–36.3) 3.97 (1.96–8.03) 
Day 0, within 120 min post-dose
n 100 100 – –
Onset of bronchodilationa, n (%) 78 (78.0) 64 (64.0) 14.0 (1.6–26.4) 2.03 (1.07–3.89) 
Day 84, within 5 min post-dose
n 98 100 – –
Onset of bronchodilationa, n (%) 16 (16.3) 2 (2.0) 14.3 (6.5–22.1) 9.58 (2.14–42.90) 
Day 84, within 120 min post-dose
n 98 97 – –
Onset of bronchodilationa, n (%) 50 (51.0) 34 (35.1) 16.0 (2.3–29.7) 1.93 (1.08–3.43) 
Data are shown as number (%) of patients achieving an onset of bronchodilation 
CI  confidence interval
a Onset of bronchodilation defined as an increase of at least 12% in forced expiratory volume in 1 second from pre-dose value


























Fluticasone/salmeterol 100/50 µg or 250/50 µg b.i.d. (n = 100)
Fluticasone/formoterol 100/10 µg or 250/10 µg b.i.d. (n = 101)



























Fluticasone/salmeterol 100/50 µg or 250/50 µg b.i.d. (n = 100)
Fluticasone/formoterol 100/10 µg or 250/10 µg b.i.d. (n = 98)
LS mean dierence: 2.79% (95% CI 0.65–4.93); 
P = 0.011
(a) (b)
Fig. 2  Percentage change in FEV1 from pre-dose to each post-dose time point on (a) day 0 and (b) day 84 (intention-to-
treat population). Data are shown as percentage change in LS mean FEV1 from baseline ± standard error. * P ≤ 0.05 versus 
fluticasone/salmeterol. b.i.d. twice daily, FEV1 forced expiratory volume in 1 second, LS least-squares
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significant (overall LS mean treatment 
difference: 0.060 L [95% CI 0.008–0.113]; 
P = 0.024; Table 3).
DISCUSSION
The authors have previously reported 
that fluticasone/formoterol combination 
therapy provides s imilar  ef f icacy to 
f luticasone/salmeterol  over 12 weeks 
of treatment in adults with mild-to-
moderate-severe persistent asthma [16]. 
The results of the post-hoc analyses presented 
here provide further evidence that fluticasone/
formoterol produces significantly faster 
bronchodilation than fluticasone/salmeterol. 
Using a definition for onset of bronchodilation 
consistent with those used by other investigators 
[15], the authors showed that fluticasone/
formoterol was superior to fluticasone/salmeterol 
for onset of bronchodilation on the first day of 
treatment. Importantly, this effect was maintained 
after 12 weeks of therapy. Moreover, the odds of 
a patient responding to treatment (assessed by 
onset of bronchodilation) within 5 min of dosing 
were almost four-times higher with fluticasone/




Change from baseline in FEV1, L Between-treatment 







5 0.296 (0.228, 0.365) 0.147 (0.078, 0.216) 0.149 (0.072, 0.226) <0.001
10 0.333 (0.265, 0.401) 0.206 (0.137, 0.275) 0.127 (0.050, 0.204) 0.001
30 0.402 (0.333, 0.470) 0.272 (0.203, 0.341) 0.130 (0.053, 0.207) 0.001
60 0.410 (0.342, 0.479) 0.335 (0.266, 0.404) 0.076 (–0.002, 0.153) 0.055
90 0.443 (0.375, 0.511) 0.336 (0.267, 0.405) 0.107 (0.030, 0.184) 0.007
120 0.441 (0.372, 0.509) 0.359 (0.290, 0.428) 0.081 (0.004, 0.159) 0.039
Overall 0.388 (0.323, 0.452) 0.276 (0.211, 0.341) 0.112 (0.042, 0.181) 0.002
Day 84
5 0.113 (0.062, 0.164) 0.077 (0.026, 0.128) 0.036 (−0.026, 0.098) 0.257
10 0.187 (0.136, 0.238) 0.123 (0.072, 0.174) 0.064 (0.002, 0.126) 0.043
30 0.208 (0.157, 0.259) 0.121 (0.070, 0.172) 0.087 (0.025, 0.149) 0.006
60 0.214 (0.163, 0.265) 0.154 (0.103, 0.205) 0.060 (−0.002, 0.122) 0.058
90 0.226 (0.175, 0.277) 0.170 (0.119, 0.221) 0.056 (−0.006, 0.118) 0.077
120 0.255 (0.204, 0.305) 0.196 (0.145, 0.247) 0.059 (−0.003, 0.121) 0.064
Overall 0.200 (0.155, 0.246) 0.140 (0.095, 0.186) 0.060 (0.008, 0.113) 0.024
Data are shown as least-squares mean
FEV1 forced expiratory volume in 1 second
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formoterol than with fluticasone/salmeterol on 
the first day of treatment and almost 10-fold 
higher after 12 weeks of therapy. Similarly, the 
odds of a patient having a response to treatment 
within 120 min of dosing were approximately 
twice as great with fluticasone/formoterol as with 
fluticasone/salmeterol on both days 0 and 84. 
Small differences in mean percentage FEV1
reversibility at baseline were observed between the 
two treatment groups. However, this is unlikely to 
have affected the results of the analyses. These 
findings suggest that consistently more patients 
achieve bronchodilation with fluticasone/
formoterol than with fluticasone/salmeterol.
The present analyses also consistently 
demonstrated differences in favor of fluticasone/
formoterol over fluticasone/salmeterol for 
changes in FEV1, a clinically important measure 
for the practicing physician. The effects of both 
therapies were larger on day 0 than on day 84, 
as would be expected given the improvement in 
FEV1 during the course of treatment. The lower 
proportion of patients responding to treatment 
at day 84 compared with day 0 reflects the fact 
that lung function had improved from baseline 
during the course of the study, as indicated by 
pre-dose FEV1, and so patients were less likely to 
achieve the FEV1 reversibility of ≥12% used to 
define bronchodilation.
In interpreting the findings reported here, it 
is important to bear in mind that they are from 
post-hoc analyses of data from an open-label 
study. However, onset of bronchodilation was a 
pre-specified secondary endpoint in the original 
study, and these post-hoc analyses strengthen 
the earlier data. Furthermore, the measures 
evaluated were physical and objective, rather 
than subjective [17], so it was not deemed likely 
that the absence of blinding had a detrimental 
effect on the results. 
In this study, the fluticasone/formoterol 
combination contained 10 μg formoterol 
and the fluticasone/salmeterol combination 
contained 50 μg salmeterol. Formoterol is a 
full agonist, whereas salmeterol is a partial 
agonist; therefore, a lower dose of formoterol 
is needed for equipotent effects, and 12 μg 
formoterol is considered equipotent to 50 μg 
salmeterol. A clear dose-effect relationship has 
been demonstrated for formoterol, but not for 
salmeterol [18]. Higher doses of formoterol 
provided increased efficacy in protecting against 
methacholine-induced bronchoconstriction in 
a study in asthma patients, whereas salmeterol 
showed a much flatter dose-response curve [19]. 
As such, 50 μg is the highest available dose of 
salmeterol, but a higher dose of formoterol 
is available with the fluticasone/formoterol 
combination (500/20 μg). 
Palmqvist et al. reported faster median 
onset of bronchodilation with higher doses of 
formoterol (3.6 min for 24 μg vs. 12.4 min for 
12 μg) [15]; therefore, it would be expected that 
there would be even greater differences in the 
onset of action between fluticasone/formoterol 
and fluticasone/salmeterol if the highest 
available doses were compared. However, it is 
unlikely that a higher dose of salmeterol would 
have affected the outcomes in the present study, 
given the lack of a clear dose-effect relationship 
for the drug, and the slower onset of action 
resulting from its mechanism of action [20]. 
Full and partial agonists differ in their effects on 
beta2-receptors, which occur in either activated 
or inactivated conformations and oscillate 
between the two states. Partial agonists are 
thought to stabilize the conformations, whereas 
full agonists move the balance completely 
towards the activated form [20]. Pharmacological 
differences between treatments may, therefore, 
be associated with clinically relevant differences 
for the management of asthma.
The more rapid onset of bronchodilation 
with fluticasone/formoterol compared with 
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fluticasone/salmeterol is consistent with findings 
of other studies [13–15, 21]. Differences favoring 
a formoterol-containing therapy (formoterol/
budesonide) were found for mean FEV1 at 
3 min post-dose and average FEV1 from 0–15 min 
post-dose [14], as well as for recovery from 
methacholine-induced bronchoconstriction [19]. 
Interestingly, assessment of patient perception 
of the onset of bronchodilation showed that 
the difference between the formoterol- and 
salmeterol-containing treatments (which was 
similar to that observed in the present study) was 
perceptible to patients [19]. Patient assessment 
of difficulty in breathing showed significantly 
greater improvement at 1 min after budesonide/
formoterol inhalation than after salmeterol/
fluticasone inhalation during recovery from 
methacholine-induced bronchoconstriction. 
This is important because evidence shows that 
patients prefer asthma maintenance medication 
when they are satisfied with how quickly they 
can feel it beginning to work [10]. Indeed, a 
group of patients who were nonadherent to their 
controller medications cited being able to feel a 
medication working soon after administration as 
a factor that could improve their adherence [22]. 
In real-world clinical practice, many patients 
with asthma remain uncontrolled [23] so may 
be more appreciative of controller therapy that 
they can perceive as working quickly. Patient 
perception has an important influence on 
medication use, with patients reporting that being 
able to feel their asthma medication working 
straight away would help remind them to take 
their medication in the future [24]. This suggests 
that initial impressions of the effectiveness of 
asthma medications may be a key factor in future 
medication use. A fast onset of bronchodilatory 
action will provide positive reinforcement for 
continuing with the medication.
The speed of onset of bronchodilation 
with an LABA has also been identified as a 
key attribute of an ICS/LABA combination 
therapy for asthma by primary and secondary 
care asthma specialists, and a broader group of 
physicians with a specialist interest in asthma 
treatment across Europe [25]. The relevance 
of this parameter has also been indicated by a 
consensus panel of practicing physicians, with 
the suggestion that a rapid onset of LABA action 
may promote adherence of patients to their 
combination therapy [26]. 
Furthermore, natural variations in lung 
function occur due to diurnal rhythms, with 
pulmonary function often poorest in the 
early morning, and this variation often can be 
exaggerated in patients with uncontrolled and/
or severe asthma [27, 28]. Hence, therapies with 
a rapid onset of action following morning dosing 
may help patients to perform morning activities 
sooner than is possible with slower-acting 
therapies. Indeed, a double-blind, cross-over 
study of 442 patients with chronic obstructive 
pulmonary disease showed that budesonide/
formoterol therapy provided a more rapid onset of 
effect than fluticasone/salmeterol therapy and was 
associated with greater improvements in patients’ 
abilities to perform morning activities [29]. 
In conclusion, these post-hoc analyses 
have provided strong additional evidence that 
fluticasone/formoterol has a more rapid onset 
of bronchodilation than fluticasone/salmeterol. 
By assessing both a pre-determined definition 
of onset of bronchodilation and mean changes 
in FEV1 over a 120-min post-dose period, this 
study has revealed significantly faster onset of 
bronchodilation with fluticasone/formoterol 
compared with fluticasone/salmeterol, which 
was maintained over a 12-week treatment 
period. This benefit is consistent with the well-
documented rapid effects of formoterol, and 
may facilitate treatment adherence among 
patients with asthma, and help them to perform 
morning activities sooner.
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